SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 197 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $402,234 | +3.1% | 128,100 | +36.1% | 0.01% | -16.7% |
Q2 2022 | $390,000 | -28.8% | 94,100 | 0.0% | 0.01% | -14.3% |
Q1 2022 | $548,000 | -56.3% | 94,100 | -43.5% | 0.01% | -50.0% |
Q4 2021 | $1,253,000 | -4.2% | 166,476 | +14.7% | 0.01% | -6.7% |
Q3 2021 | $1,308,000 | -2.9% | 145,100 | +28.7% | 0.02% | -16.7% |
Q2 2021 | $1,347,000 | -56.8% | 112,765 | -54.8% | 0.02% | -73.5% |
Q1 2021 | $3,120,000 | +78.6% | 249,206 | +122.5% | 0.07% | +74.4% |
Q4 2020 | $1,747,000 | +144.0% | 112,000 | +40.0% | 0.04% | +62.5% |
Q2 2020 | $716,000 | +6.9% | 80,000 | -23.8% | 0.02% | -35.1% |
Q1 2020 | $670,000 | +23.4% | 105,000 | +61.5% | 0.04% | +105.6% |
Q4 2019 | $543,000 | +71.3% | 65,000 | +85.7% | 0.02% | +12.5% |
Q3 2019 | $317,000 | -94.7% | 35,000 | -93.7% | 0.02% | -94.7% |
Q2 2019 | $6,002,000 | +1697.0% | 557,200 | +1492.0% | 0.30% | +1583.3% |
Q1 2019 | $334,000 | -61.9% | 35,000 | -43.2% | 0.02% | -73.5% |
Q2 2018 | $876,000 | – | 61,667 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |